Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Farooqui, Janet Valdez, S. Martyr, G. Aue, N. Saba, C. Niemann, S. Herman, X. Tian, G. Marti, S. Soto, Thomas Hughes, Jade Jones, A. Lipsky, S. Pittaluga, M. Stetler-Stevenson, C. Yuan, Yuh-Shan Lee, L. Pedersen, C. Geisler, K. Calvo, D. Arthur, I. Maric, R. Childs, N. Young, A. Wiestner (2015)Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
The Lancet. Oncology, 16 2
G. Dighiero, K. Maloum, B. Desablens, B. Cazin, M. Navarro, R. Leblay, M. Leporrier, J. Jaubert, G. Lepeu, B. Dreyfus, J. Binet, P. Travade, F. Turpin, G. Tertian, Agnès Bichoffe (1998)Chlorambucil in Indolent Chronic Lymphocytic Leukemia
The New England Journal of Medicine, 338
T. Shanafelt, H. Gunderson, T. Call (2010)Commentary: chronic lymphocytic leukemia--the price of progress.
The oncologist, 15 6
N. Jain, Qiushi Chen, T. Ayer, W. Wierda, S. O'brien, M. Keating, H. Kantarjian, J. Chhatwal (2015)Prevalence and Economic Burden of Chronic Lymphocytic Leukemia (CLL) in the Era of Oral Targeted Therapies
Clinical Lymphoma, Myeloma & Leukemia, 15
S. Mailankody, V. Prasad (2015)Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs.
JAMA oncology, 1 4
S. Stilgenbauer, B. Eichhorst, J. Schetelig, S. Coutre, J. Seymour, Talha Munir, S. Puvvada, C. Wendtner, A. Roberts, W. Jurczak, S. Mulligan, S. Böttcher, M. Mobasher, Ming Zhu, Monali Desai, B. Chyla, M. Verdugo, S. Enschede, E. Cerri, R. Humerickhouse, G. Gordon, M. Hallek, W. Wierda (2016)Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
The Lancet. Oncology, 17 6
V. Prasad, S. Mailankody (2017)Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval
JAMA Internal Medicine, 177
S. Rajkumar, J. Harousseau (2016)Next-generation multiple myeloma treatment: a pharmacoeconomic perspective.
Blood, 128 24
Jennifer Brown, P. Hillmen, S. O'brien, J. Barrientos, N. Reddy, S. Coutre, C. Tam, S. Mulligan, U. Jaeger, P. Barr, R. Furman, T. Kipps, F. Cymbalista, P. Thornton, F. Caligaris‐cappio, J. Delgado, M. Montillo, S. Devos, C. Moreno, J. Pagel, J. Burger, D. Chung, Jennifer Lin, L. Gau, B. Chang, J. Mcgreivy, D. James, J. Byrd (2014)Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATETM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
B. Hillner, Thomas Smith (2009)Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 13
J. Sharman, S. Coutre, R. Furman, B. Cheson, J. Pagel, P. Hillmen, J. Barrientos, A. Zelenetz, T. Kipps, I. Flinn, P. Ghia, M. Hallek, B. Coiffier, S. O'brien, E. Tausch, K. Kreuzer, Wendy Jiang, T. Jahn, M. Lazarov, S. Stilgenbauer (2014)Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial
Journal of Clinical Oncology, 32
P. Bach (2009)Limits on Medicare's ability to control rising spending on cancer drugs.
The New England journal of medicine, 360 6
Jeffrey Betcher, E. Dow, N. Khera (2016)Oral Chemotherapy in Patients with Hematological Malignancies—Care Process, Pharmacoeconomic and Policy Implications
Current Hematologic Malignancy Reports, 11
R. Siegel, K. Miller, A. Jemal (2017)Cancer statistics, 2017
CA: A Cancer Journal for Clinicians, 67
A. Tefferi, H. Kantarjian, S. Rajkumar, Lawrence Baker, J. Abkowitz, J. Adamson, R. Advani, J. Allison, K. Antman, R. Bast, John Bennett, E. Benz, N. Berliner, J. Bertino, R. Bhatia, S. Bhatia, D. Bhojwani, C. Blanke, C. Bloomfield, L. Bosserman, H. Broxmeyer, J. Byrd, F. Cabanillas, G. Canellos, B. Chabner, A. Chanan-Khan, B. Cheson, B. Clarkson, S. Cohn, G. Colón-Otero, Jorge Cortes, S. Coutre, M. Cristofanilli, W. Curran, G. Daley, D. DeAngelo, H. Deeg, L. Einhorn, H. Erba, F. Esteva, E. Estey, I. Fidler, J. Foran, S. Forman, E. Freireich, C. Fuchs, J. George, M. Gertz, S. Giralt, H. Golomb, P. Greenberg, J. Gutterman, R. Handin, Samuel Hellman, P. Hoff, R. Hoffman, W. Hong, M. Horowitz, G. Hortobagyi, C. Hudis, J. Issa, B. Johnson, P. Kantoff, K. Kaushansky, D. Khayat, F. Khuri, T. Kipps, M. Kripke, R. Kyle, R. Larson, T. Lawrence, Ross Levine, M. Link, S. Lippman, S. Lonial, G. Lyman, M. Markman, J. Mendelsohn, N. Meropol, Y. Messinger, T. Mulvey, S. O'brien, R. Perez-soler, R. Pollock, J. Prchal, O. Press, J. Radich, K. Rai, S. Rosenberg, J. Rowe, H. Rugo, C. Runowicz, B. Sandmaier, A. Saven, A. Schafer, C. Schiffer, M. Sekeres, R. Silver, L. Siu, D. Steensma, F. Stewart, W. Stock, R. Stone, R. Storb, L. Strong, M. Tallman, M. Thompson, N. Ueno, R. Etten, J. Vose, P. Wiernik, E. Winer, A. Younes, A. Zelenetz, C. Lemaistre (2015)In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.
Mayo Clinic proceedings, 90 8
A. Gopal, B. Kahl, S. Vos, N. Wagner-Johnston, S. Schuster, W. Jurczak, I. Flinn, C. Flowers, P. Martin, A. Viardot, K. Blum, A. Goy, A. Davies, P. Zinzani, M. Dreyling, D. Johnson, L. Miller, Leanne Holes, Daniel Li, R. Dansey, W. Godfrey, G. Salles (2014)PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
The New England journal of medicine, 370 11
S. Dusetzina (2016)Drug Pricing Trends for Orally Administered Anticancer Medications Reimbursed by Commercial Health Plans, 2000-2014.
JAMA oncology, 2 7
J. Burger, A. Tedeschi, P. Barr, T. Robak, C. Owen, P. Ghia, O. Bairey, P. Hillmen, N. Bartlett, Jianyong Li, D. Simpson, S. Grosicki, S. Devereux, H. McCarthy, S. Coutre, H. Quach, G. Gaidano, Z. Maslyak, D. Stevens, A. Janssens, F. Offner, J. Mayer, M. O'Dwyer, A. Hellmann, A. Schuh, T. Siddiqi, A. Polliack, C. Tam, Deepali Suri, M. Cheng, F. Clow, L. Styles, D. James, T. Kipps (2015)Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
The New England journal of medicine, 373 25
J. Byrd, Jennifer Brown, S. O'brien, J. Barrientos, N. Kay, N. Reddy, S. Coutre, C. Tam, S. Mulligan, U. Jaeger, S. Devereux, P. Barr, R. Furman, T. Kipps, F. Cymbalista, C. Pocock, P. Thornton, F. Caligaris‐cappio, T. Robak, J. Delgado, S. Schuster, M. Montillo, A. Schuh, S. Vos, D. Gill, A. Bloor, C. Dearden, C. Moreno, Jeffrey Jones, A. Chu, M. Fardis, J. Mcgreivy, F. Clow, D. James, P. Hillmen (2014)Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
The New England journal of medicine, 371 3
S. Dusetzina, H. Huskamp, Aaron Winn, E. Basch, N. Keating (2017)Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws
JAMA Oncology, 4
A. Lyles (2017)Pharmacy Benefit Management Companies: Do They Create Value in the US Healthcare System?
V. Prasad, S. Mailankody (2016)The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable.
Mayo Clinic proceedings, 91 6
Qiushi Chen, N. Jain, T. Ayer, W. Wierda, C. Flowers, S. O'brien, M. Keating, H. Kantarjian, J. Chhatwal (2017)Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35 2
D. Miklos, C. Cutler, M. Arora, E. Waller, M. Jagasia, I. Pusic, M. Flowers, A. Logan, R. Nakamura, B. Blazar, Yunfeng Li, Stephen Chang, I. Lal, J. Dubovsky, D. James, L. Styles, S. Jaglowski (2017)Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.
Blood, 130 21
H. Kantarjian, T. Fojo, M. Mathisen, L. Zwelling (2013)Cancer drugs in the United States: Justum Pretium--the just price.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 28
Journal of Health Economics
S. Kircher, C. Meeker, H. Nimeiri, D. Geynisman, S. Zafar, V. Shankaran, J. Souza, Y. Wong (2016)The Parity Paradigm: Can Legislation Help Reduce the Cost Burden of Oral Anticancer Medications?
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 19 1
C. Tam, S. O'brien, W. Wierda, H. Kantarjian, S. Wen, K. Do, D. Thomas, J. Cortes, S. Lerner, M. Keating (2008)Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.
Blood, 112 4
Thomas Lee, E. Emanuel (2008)Tier 4 drugs and the fraying of the social compact.
The New England journal of medicine, 359 4
M. Dreyling, W. Jurczak, M. Jerkeman, Rodrigo Silva, C. Rusconi, M. Trněný, F. Offner, D. Caballero, C. João, M. Witzens‐Harig, G. Hess, I. Bence‐Bruckler, Seok-Goo Cho, J. Bothos, J. Goldberg, C. Enny, S. Traina, S. Balasubramanian, N. Bandyopadhyay, Steven Sun, J. Vermeulen, A. Rizo, S. Rule (2016)Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
The Lancet, 387
P. Thompson, C. Tam, S. O'brien, W. Wierda, F. Stingo, W. Plunkett, Susan Smith, H. Kantarjian, E. Freireich, M. Keating (2016)Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.
Blood, 127 3
A. Wiestner (2015)The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia
K. Fischer, P. Cramer, R. Busch, S. Böttcher, J. Bahlo, J. Schubert, K. Pflüger, S. Schott, V. Goede, S. Isfort, J. Tresckow, A. Fink, A. Bühler, D. Winkler, K. Kreuzer, P. Staib, M. Ritgen, M. Kneba, H. Döhner, B. Eichhorst, M. Hallek, S. Stilgenbauer, C. Wendtner (2012)Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 26
T. Shanafelt, B. Borah, H. Finnes, K. Chaffee, W. Ding, J. Leis, A. Chanan-Khan, S. Parikh, S. Slager, N. Kay, T. Call (2015)Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels.
Journal of oncology practice, 11 3
R. Furman, J. Sharman, S. Coutre, B. Cheson, J. Pagel, P. Hillmen, J. Barrientos, A. Zelenetz, T. Kipps, I. Flinn, P. Ghia, H. Eradat, T. Ervin, N. Lamanna, B. Coiffier, A. Pettitt, Shuo Ma, S. Stilgenbauer, P. Cramer, Maria Aiello, D. Johnson, L. Miller, Daniel Li, T. Jahn, R. Dansey, M. Hallek, S. O'brien (2014)Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
The New England journal of medicine, 370 11
A. Davidoff, M. Erten, T. Shaffer, J. Shoemaker, I. Zuckerman, N. Pandya, M. Tai, X. Ke, B. Stuart (2013)Out‐of‐pocket health care expenditure burden for Medicare beneficiaries with cancer
M. Siddiqui, S. Rajkumar (2012)The high cost of cancer drugs and what we can do about it.
Mayo Clinic proceedings, 87 10
M. Hallek, K. Fischer, G. Fingerle-Rowson, A. Fink, R. Busch, J. Mayer, M. Hensel, G. Hopfinger, G. Hess, U. Grünhagen, Matthias Bergmann, J. Catalano, P. Zinzani, F. Caligaris‐cappio, J. Seymour, A. Berrebi, U. Jäger, B. Cazin, M. Trněný, A. Westermann, C. Wendtner, B. Eichhorst, P. Staib, A. Bühler, D. Winkler, T. Zenz, S. Böttcher, M. Ritgen, M. Mendila, M. Kneba, H. Döhner, S. Stilgenbauer (2010)Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
The Lancet, 376
S. Mailankody, V. Prasad (2016)Implications of Proposed Medicare Reforms to Counteract High Cancer Drug Prices.
JAMA, 316 3
Purpose of Review Small molecule tyrosine kinase inhibitors (TKIs) and BCL2 inhibitors are oral targeted therapies that have changed the treatment approach to patients with chronic lymphocytic leukemia (CLL). The aim of this review is to summarize the relevant literature on the economic impact of oral novel therapies for the treatment of CLL and discuss the underlying factors and suggested solutions for high drug prices. Recent Findings The cost of therapy for CLL has increased substantially since the introduction of oral therapies. This increase in cost is caused by multiple factors including cost of drug development, alternate reimbursement patterns, lack of transparency, and lack of free market competition. Summary Oral therapies for CLL have dramatically increased costs for both patients and payers. Some solutions to overcome this include value-based pricing, transparency, and legal action that allow Medicare to negotiate drug prices with manufacturers. . . . . . Keywords CLL Ibrutinib Idelalisib Venetoclax Drug costs Pharmacoeconomics, financial toxicity Introduction PFS of 4.2 years , while those with del(17p) have a median PFS of 1 year . Chronic lymphocytic leukemia (CLL) is the most com- B cell receptor signaling plays a central role in disease path- mon leukemia in the
Current Hematologic Malignancy Reports – Springer Journals
Published: Jul 7, 2018
Access the full text.
Sign up today, get DeepDyve free for 14 days.